Merck, Keytruda and FDA
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
1d
GlobalData on MSNPfizer sets sights on Summit’s bispecific in combo with its ADCsSummit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results